Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial

PHASE4UnknownINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

August 31, 2006

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Advair

DRUG

Flovent

Trial Locations (10)

T2V 1P9

RECRUITING

University of Calgary, Calgary

T5G 3G6

RECRUITING

Links Clinic, Edmonton

T6G 2B7

RECRUITING

University of Alberta Hospital, Edmonton

T6L 5X8

RECRUITING

Grey Nuns Hospital, Edmonton

T1J 1W5

RECRUITING

Lethbridge Regional Hospital, Lethbridge

T9A 3B8

RECRUITING

Wetaskiwin Lung Laboratory, Wetaskiwin

V7L 2N3

RECRUITING

Lion's Gate Hospital, North Vancouver

V5Z 3J5

RECRUITING

Vancouver General Hospital, Vancouver

V6Z 1Y6

RECRUITING

St. Paul' Hospital, Vancouver

S7N 0W8

RECRUITING

Royal University Hospita, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of British Columbia

OTHER

NCT00120978 - Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial | Biotech Hunter | Biotech Hunter